Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenqi capsule is a Traditional Chinese Medicine (TCM) patent drug primarily composed of extracts from *Radix Ginseng* (Ren Shen) and *Radix Astragali* (Huang Qi). It is widely utilized in China for the management of cardiovascular conditions, particularly as an adjunctive therapy for patients with coronary artery disease (CAD) and those recovering from percutaneous coronary intervention (PCI). The formulation is designed to replenish "Qi" and nourish blood, which clinically translates to improving myocardial energy metabolism, enhancing microcirculation, and providing antioxidant and anti-inflammatory protection to the myocardium. In the context of post-PCI care, it is evaluated for its potential to reduce major adverse cardiovascular events (MACE) and improve the quality of life by addressing symptoms like fatigue and palpitations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shenqi capsule.